• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Combined use of non-biological arti fi cial liver treatments for patients with acute liver failure complicated by multiple organ dysfunction syndrome

    2014-03-20 01:37:11
    World journal of emergency medicine 2014年3期

    Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China

    Corresponding Author:Mao-qin Li, Email: limaoqinxi@126.com

    Combined use of non-biological arti fi cial liver treatments for patients with acute liver failure complicated by multiple organ dysfunction syndrome

    Mao-qin Li, Jun-xiang Ti, Yun-hang Zhu, Zai-xiang Shi, Ji-yuan Xu, Bo Lu, Jia-qiong Li, Xiao-meng Wang, Yan-jun Xu

    Department of Intensive Care, Xuzhou Central Hospital, Affiliated to School of Medicine, Southeast University, Xuzhou 221009, China

    Corresponding Author:Mao-qin Li, Email: limaoqinxi@126.com

    BACKGROUND:Acute liver failure (ALF) caused by viral and non-viral hepatitis is often accompanied with severe metabolic disorders, the accumulation of toxic substances and continuous release and accumulation of a large number of endogenous toxins and inflammatory mediators. The present study aimed to investigate the effects of various combined non-biological arti fi cial liver treatments for patients with acute liver failure (ALF) complicated by multiple organ dysfunction syndrome (MODS).

    METHODS:Thirty-one patients with mid- or late-stage liver failure complicated by MODS (score 4) were randomly divided into three treatment groups: plasmapheresis (PE) combined with hemoperfusion (HP) and continuous venovenous hemodiafiltration (CVVHDF), PE+CVVHDF, and HP+CVVHDF, respectively. Heart rate (HR) before and after treatment, mean arterial pressure (MAP), respiratory index (PaO2/FiO2), hepatic function, platelet count, and blood coagulation were determined.

    RESULTS:Signi fi cant improvement was observed in HR, MAP, PaO2/FiO2, total bilirubin (TBIL) and alanine aminotransferase (ALT) levels after treatment (P<0.05). TBIL and ALT decreased more signi fi cantly after treatment in the PE+CVVHDF and PE+HP+CVVHDF groups (P<0.01). Prothrombin time (PT) and albumin were signi fi cantly improved only in the PE+CVVHDF and PE+HP+CVVHDF groups (P<0.05). TBIL decreased more significantly in the PE+HP+CVVHDF group than in the HP+CVVHDF and PE+CVVHDF groups (P<0.05). The survival rate of the patients was 58.1% (18/31), viral survival rate 36.4% (4/11), and non-viral survival rate 70% (14/20).

    CONCLUSION:Liver function was relatively improved after treatment, but PE+HP+CVVHDF was more efficient for the removal of toxic metabolites, especially bilirubin. The survival rate was signi fi cantly higher in the patients with non-viral liver failure than in those with viral liver failure.

    Severe acute liver failure; Artificial liver; Plasma exchange; Hemoperfusion; Continuous veno-venous hemodia fi ltration

    INTRODUCTION

    Acute liver failure (ALF) caused by viral and non-viral hepatitis is often accompanied with severe metabolic disorders, the accumulation of toxic substances and continuous release and accumulation of a large number of endogenous toxins and inflammatory mediators. In turn, this promotes liver damage and inhibits the regeneration of liver cells, creating a vicious cycle. Despite internal conventional therapies such as protecting liver function, improving jaundice, and a variety of medical support treatments, the clinical mortality of patients with severe ALF is still as high as 70%.[1]Artificial liver support system (ALSS) replaces liver function temporarily and partially, while removingall harmful substances and supplying biological active substances to create a good environment for regeneration and functional recovery of hepatic cells of the patient. Due to the limited effect of single ALSS, various combinations of non-biological artificial liver methods have become the hot topic. The present study aimed to observe the efficacy and safety of three combined ALSS regimens for the treatment of severe ALF: plasmapheresis (PE) combined with hemoperfusion (HP) and continuous venovenous hemodiafiltration (CVVHDF), PE+CVVHDF and HP+CVVHDF.

    METHODS

    General information

    Thirty-one patients with severe ALF were admitted to intensive care unit of Xuzhou Central Hospital from January 2007 to March 2013. The patients met the following criteria: liver score IV (total bilirubin>240 μmol/L) according to multiple organ dysfunction syndrome (MODS) score; and severe ALF complicated with MODS. In this series, 22 patients were male, and 9 were female, with a mean age of 38.1±14.8 years (range 20–82 years). Their chronic health evaluation II score (APACHE II) was 28.7±7.8, and sequential organ failure assessment score (SOFA score) was 13.67±3.31. Primary diseases in these patients included acute viral hepatitis (1 patient), ALF and chronic toxicity (10 patients), non-viral liver injury (cardiac surgery in 1 patient, poisoning in 6, pregnancy in 5, poisonous mushroom in 1, severe infection in 5, and others in 2). Liver failure staging[6]showed that all patients were in the stage of advanced liver failure with prothrombin activity (PTA)≤30%, including 23 patients with renal dysfunction, 15 patients with hepatic encephalopathy, 21 patients with gastrointestinal bleeding, 31 patients with blood clotting abnormalities, and 15 patients with circulatory dysfunction.

    The trial protocol was approved by the Ethics Committee of Xuezhou Central Hospital. All patients or their legal surrogates provided written informed consent for participation.

    Treatment

    In addition to conventional medicine and supportive treatment, the 31 patients were randomly treated with the following three regimens: PE+HP+CVVHDF, PE+CVVHDF or HP+CVVHDF.

    In the PE+HP +CVVHDF group, after establishing temporary access of the femoral vein or jugular vein catheterization, patients received plasmapheresis at bedside using a Swiss Campbell PF2000N plasma separator (permutation of fresh plasma 1 500–2 500 mL, plasma exchange fl ow rate 80–120 mL/min, plasma separation speed 25–30 mL/min, and replacement time 2–3 hours). After a single plasma exchange was completed, patients received HP, using neutral macroporous resin ( a HA330-II type hemoperfusion device produced by Zhuhai Franc). The hemoperfusion device was removed while its perfusion adsorption capacity for saturation and blood perfusion lasted 2–3 hours. Then, the patients were subjected to CVVHDF for (32.4±24.4) hours (range 10–49 hours).

    In the PE+CVVHDF group, patients underwent CVVHDF therapy after plasmapheresis. In the HP +CVVHDF group, patients underwent CVVHDF after HP.

    In the study, the 31 patients received a total of 81 treatments, including 23 treatments with PE+HP+CVVHDF, 26 treatments with PE+CVVHDF, and 32 treatments with HP+CVVHDF.

    Indicators

    The following indicators were observed: consciousness, heart rate (HR), mean arterial pressure (MAP), arterial blood gas (pH, PaO2, PaCO2), hepatic and renal function, blood count, electrolytes, and coagulation of each patient before and after treatment in the three groups.

    Statistical analysis

    Data of the three groups were expressed as the mean±SD. All analyses were performed using the SPSS 12.0 statistical package (SPSS Inc., Chicago, IL). Twoway ANOVA was used to compare the data between the three groups. All tests were two-tailed, and P values less than 0.05 were considered statistically signi fi cant.

    RESULTS

    General data

    There were no significant differences in age, SOFA score and treatment time between the three groups (P> 0.05) (Table 1).

    Table 1. Patients' age, SOFA score, and treatment time (mean ±SD)

    Table 2. HR, MAP, PaO2/FiO2and PLT before and after treatment (mean±SD)

    Table 3. Coagulation and liver function (mean ±SD)

    HR, MAP, PaO2/FiO2and platelets before and after treatment

    There were no significant differences in platelet changes before and after treatment in the three groups (P>0.05). HR, MAP and PaO2/FiO2increased more significantly after treatment than before treatment in the three groups (P<0.05). HR and PaO2/FiO2showed a significant change between the PE+HP+CVVHDF and HP+CVVHDF groups (P<0.05) (Table 2).

    Coagulation and liver function before and after treatment

    Total bilirubin (TBIL) and alanine aminotransferase (ALT) levels decreased more significantly after treatment than before treatment (P<0.05) in the PE+HP+ CVVHDF group and PE+CVVHDF group (P<0.01). However, TBIL decreased more significantly in the PE+HP+CVVHDF group than in the HP+CVVHDF and PE+CVVHDF groups. The changes of prothrombin time (PT) and albumin (ALB) level were statistically significant between the PE+HP+CVVHDF and PE+ CVVHDF groups (P<0.05) (Table 3).

    Clinical outcomes

    Of the 31 patients, 18 (58.1%) survived after treatment with the ALSS. In these patients, 4 were from the 11 patients with virus-caused liver failure, and 14 were from the 20 patients with non-virus-caused liver failure.

    DISCUSSION

    ALF is characterized by rapid onset, progression, and poor prognosis.[2]Actually, it is a kind of MODS. The treatment effect of simple conventional supportive care is not satisfactory, and blood purification technology can replace liver metabolic functions, thus supporting multiple organ function effectively.[3]The combined use of ALSS treatments plays a crucial role in decreasing the level of serum bilirubin, removing or reducing toxic substances, and improving the internal environment of ALF in liver failure patients. It has been reported that the survival rate of patients was 80%–90 % in the early course of ALF. Their interim survival rate was 60%–70%, while the survival rate of patients with advanced ALF was less than 20%.[4]Ye et al[5]reported that the survival rate was 48.3% for chronic severe hepatitis B patients treated with hemo fi ltration and plasmapheresis. He et al[6]reported that the survival rate was 45.5% for MODS patients with ALF in the ICU after treatment with pairing plasma separation adsorption and hemofiltration. The survival rate was 42.5% for MODS patients with ALF after treatment with plasma exchange and CVVHDF.[7]In our study, the liver function score was≥IV according to MODS score, and PTA was less than 30%. All patients were in the stage of advanced liver failure according to liver failure treatment guidelines.[8]We used three combined non-biological arti fi cial liver therapies, and 18 (58.1%) of the 31 patients survived. A significant improvement was observed in thesurvival rate compared to another study.[7]

    In our study, the survival rate of patients with nonvirus-caused liver failure was 70%, but the survival rate of patients with virus-caused liver failure was 36.4%. The finding suggested that the combined use of nonbiological artificial liver technology plays a significant role in improving the clinical outcomes. Different combinations of non-bioarti fi cial therapies were effective in improving severe metabolic disorders and removing accumulated toxic substances and inflammatory mediators caused by serious damage of liver cells. Thus, combined non-bioartificial therapies play a significant role in improving clinical outcomes. For patients with non-virus-caused severe ALF, combined ALSS plays a signi fi cant role in reducing the mortality.

    Three combined therapies with the non-biological arti fi cial liver revealed that there are signi fi cant differences in heart rate, mean arterial pressure, respiratory index after treatment compared with before treatment (P<0.05). TBIL and ALT in the PE+HP+CVVHDF group and PE+CVVHDF group decreased more significantly (P<0.01). PT and ALB changed significantly before and after treatment in the PE+HP+CVVHDF group and PE+CVVHDF group (P<0.05). The decrease of TBIL was more significant in the PE+HP+CVVHDF group than in the HP+CVVHDF and PE+CVVHDF groups. The results suggested that the combination of PE+HP+CVVHDF is more conducive to remove metabolites and scavenge poisons in addition to maintain homeostasis. PE can widely remove endogenous toxins (such as endotoxin, bilirubin, and bile acids) and macromolecules binding with plasma protein and circulating immune complexes.

    PE is not adequately effective because the small molecular weight toxins can easily pass through the blood vessel wall, and is widely distributed in tissues. HP can absorb aromatic amino acid, phenol, indole, shortchain fatty acids and others. Hemsoperfuion using HA resin perfusion, a neutral macroporous resin adsorption 500–5 000 Da major molecular weight substance, can absorb a variety of proteins binding toxins and cytotoxic substances, which inhibit regeneration of liver.[10]CVVH can continually eliminate the molecular substances, ammonia and other toxic substances such as false neurotransmitters, free fatty acids, amino acids, aromatic thiols in patients with acute liver failure, increase the content of CAMP in cerebrospinal fluid, improve energy metabolism in the brain, alleviate and ameliorate hepatic encephalopathy. CVVH can accurately control capacity, continuously and slowly remove the solute and liquid, regulate water, electrolyte and acid-base balance, and reduce the occurrence of brain edema in patients with acute liver failure.

    In conclusion, liver function was improved after three artificial liver treatments in the present study. PE+HP+CVVHDF was more effective to remove the metabolites and toxins, especially bilirubin. After treatment, the survival rate of patients with non-viruscaused liver failure was signi fi cantly higher than that of those with virus-caused liver failure.

    Funding:The study was supported by a grant from Xuzhou Municipal, China.

    Ethical approval:This study was approved by the ethical Committees of Xuzhou Central Hospital, Jiangsu Province, China.

    Con fl icts of interest:We have no con fl icts of interest to report.

    Contributors:Li MQ proposed the study and wrote the paper. All authors contributed to the design and interpretation of the study and to further drafts.

    REFERENCES

    1 Zheng Z, Li X, Li Z, Ma X. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression. Exp Ther Med 2013; 6: 929–936. Epub 2013 Jul 31.

    2 Majumdar M, Ratho R, Chawla Y, Singh MP. High levels of circulating HMGB1 as a biomarker of acute liver failure in patients with viral hepatitis E. Liver Int 2013; 33: 1341–1348.

    3 Song G, Li Y, Li M, Xuan R. Acute renal and liver failure due to acute fatty liver of pregnancy-complicated pre-eclampsia. J Obstet Gynaecol 2012; 32: 702–703.

    4 Takikawa Y, Suzuki K. Clinical epidemiology of fulminant hepatitis in Japan. Hepatol Res 2008; 38 Suppl 1: S14–18.

    5 Wu XL, Long D, Yu L, Yang JH, Zhang YC, Geng F. Urokinasetype plasminogen activator receptor as a predictor of poor outcome in patients with systemic infl ammatory response syndrome. World J Emerg Med 2013; 4: 190–195.

    6 Fang K, Wang XL. Treatment of multiple organ dysfunction syndrome by Xuebijing Injection: a clinical research. Zhongguo Zhong Xi Yi Jie He Za Zhi 2013; 33: 205–207.

    7 Li LJ, Zhang YM, Liu XL, Du WB, Huang JR, Yang Q, et al. Arti fi cial liver support system in China: a review over the last 30 years. Ther Apher Dial 2006; 10: 160–167.

    8 Chinese Society of Hepatology. Guidelines for liver failure. Chin J Hepatology 2006; 14: 543–646.

    9 Li MQ, Li JQ, Shi ZX, Xu JY, Zhang Z, Lu F, et al. Efficacy of various combined blood purification techniques for treating patients with non-viral acute liver failure. Cell Biochem Biophys 2014; 68: 571–575.

    10 Huang Z, Wang SR, Su W, Liu JY. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial 2010; 14: 596–602.

    Received January 11, 2014

    Accepted after revision July 3, 2014

    World J Emerg Med 2014;5(3):214–217

    10.5847/ wjem.j.issn.1920–8642.2014.03.010

    久久久亚洲精品成人影院| 伦理电影大哥的女人| av.在线天堂| 久久国产乱子免费精品| 狠狠狠狠99中文字幕| 最近的中文字幕免费完整| 精品人妻一区二区三区麻豆| 久久久久久久久久久免费av| 免费观看a级毛片全部| 最近视频中文字幕2019在线8| 18禁在线无遮挡免费观看视频| 欧美成人精品欧美一级黄| 97超碰精品成人国产| 熟女电影av网| 三级经典国产精品| 精品国产露脸久久av麻豆 | 99热这里只有精品一区| 国模一区二区三区四区视频| 精品人妻一区二区三区麻豆| 国产午夜福利久久久久久| 少妇丰满av| 日韩成人av中文字幕在线观看| 三级毛片av免费| 一级毛片aaaaaa免费看小| 亚洲中文字幕日韩| 精品午夜福利在线看| 亚洲精品国产av成人精品| 久久精品国产鲁丝片午夜精品| 看免费成人av毛片| 91av网一区二区| 99九九线精品视频在线观看视频| 亚洲欧美一区二区三区国产| 国产成人精品一,二区| 国内精品一区二区在线观看| www.av在线官网国产| 男女视频在线观看网站免费| 好男人在线观看高清免费视频| 日本欧美国产在线视频| 女人被狂操c到高潮| 中文字幕免费在线视频6| 老师上课跳d突然被开到最大视频| 身体一侧抽搐| 一级黄色大片毛片| 国产成人精品久久久久久| 日韩制服骚丝袜av| 一本一本综合久久| 久久久欧美国产精品| 久久热精品热| 青青草视频在线视频观看| 麻豆乱淫一区二区| kizo精华| 国产一区二区在线观看日韩| 好男人视频免费观看在线| 男人狂女人下面高潮的视频| 国产av一区在线观看免费| 久久草成人影院| 久久久久久久久久久丰满| 99热这里只有精品一区| 真实男女啪啪啪动态图| 乱码一卡2卡4卡精品| 日韩视频在线欧美| 国产午夜精品一二区理论片| 久久久久久久久久成人| 大话2 男鬼变身卡| 日本五十路高清| 欧美一级a爱片免费观看看| 精品少妇黑人巨大在线播放 | 亚洲精品色激情综合| 一边亲一边摸免费视频| 亚洲aⅴ乱码一区二区在线播放| 午夜激情福利司机影院| 老女人水多毛片| 搞女人的毛片| 波多野结衣高清无吗| 色吧在线观看| 一级毛片久久久久久久久女| 国产黄色小视频在线观看| 一本一本综合久久| 久热久热在线精品观看| 级片在线观看| 国产在线男女| 免费av不卡在线播放| 久久精品国产自在天天线| 亚洲国产精品成人综合色| 内地一区二区视频在线| 精品一区二区三区人妻视频| 激情 狠狠 欧美| 久久精品久久久久久久性| 欧美人与善性xxx| 看非洲黑人一级黄片| 亚洲高清免费不卡视频| 国产淫语在线视频| 汤姆久久久久久久影院中文字幕 | 91精品伊人久久大香线蕉| 国产在线一区二区三区精 | 欧美激情在线99| 亚洲av电影不卡..在线观看| 午夜福利在线观看免费完整高清在| 亚洲av福利一区| 熟女人妻精品中文字幕| 精品少妇黑人巨大在线播放 | 啦啦啦韩国在线观看视频| 久久久久久九九精品二区国产| 淫秽高清视频在线观看| 国产亚洲一区二区精品| 熟女电影av网| 久久久久久久午夜电影| 国产v大片淫在线免费观看| 大香蕉久久网| 国产成人精品婷婷| 啦啦啦啦在线视频资源| 亚洲经典国产精华液单| 欧美日韩精品成人综合77777| 亚洲国产欧美在线一区| 99九九线精品视频在线观看视频| 青春草亚洲视频在线观看| 欧美成人a在线观看| 久久人人爽人人片av| 亚洲一区高清亚洲精品| 国产日韩欧美在线精品| 国产精品.久久久| 久久99精品国语久久久| 欧美精品国产亚洲| 91精品伊人久久大香线蕉| 啦啦啦啦在线视频资源| 国产在线男女| 国产一级毛片七仙女欲春2| 亚洲av成人精品一二三区| 免费看美女性在线毛片视频| 2021少妇久久久久久久久久久| 国产久久久一区二区三区| 波野结衣二区三区在线| a级毛片免费高清观看在线播放| 啦啦啦啦在线视频资源| 国产黄片美女视频| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 亚洲精品色激情综合| 国产美女午夜福利| 亚洲最大成人中文| 久久精品影院6| 久久久久性生活片| 人体艺术视频欧美日本| 我要看日韩黄色一级片| 又爽又黄a免费视频| 国产免费一级a男人的天堂| 亚洲最大成人av| 亚洲欧美精品综合久久99| 插逼视频在线观看| 日韩强制内射视频| 亚洲精品乱码久久久v下载方式| 日本黄色视频三级网站网址| 综合色丁香网| 日韩视频在线欧美| 久久精品夜夜夜夜夜久久蜜豆| 99久久精品国产国产毛片| 看片在线看免费视频| 国产午夜精品久久久久久一区二区三区| 日本免费a在线| 欧美成人午夜免费资源| 色网站视频免费| 美女大奶头视频| 亚洲精品影视一区二区三区av| 免费在线观看成人毛片| 免费av不卡在线播放| 亚洲内射少妇av| 午夜激情欧美在线| 久久精品久久久久久噜噜老黄 | 99国产精品一区二区蜜桃av| 亚洲av男天堂| 午夜老司机福利剧场| 国产人妻一区二区三区在| 免费一级毛片在线播放高清视频| 亚洲电影在线观看av| 一夜夜www| 国产单亲对白刺激| 亚洲av二区三区四区| 亚洲欧洲国产日韩| 丰满少妇做爰视频| 中文字幕亚洲精品专区| www.av在线官网国产| 日韩av在线免费看完整版不卡| 亚洲精品色激情综合| av女优亚洲男人天堂| 亚洲一区高清亚洲精品| av在线亚洲专区| 中文欧美无线码| 又粗又硬又长又爽又黄的视频| 午夜爱爱视频在线播放| 联通29元200g的流量卡| 黄色配什么色好看| 欧美bdsm另类| 一个人观看的视频www高清免费观看| 久久久国产成人免费| 久久久a久久爽久久v久久| 久久久久久久久久成人| 欧美日本亚洲视频在线播放| 一边亲一边摸免费视频| 一本久久精品| 国产大屁股一区二区在线视频| 欧美区成人在线视频| 高清日韩中文字幕在线| 丰满少妇做爰视频| 久久精品国产鲁丝片午夜精品| 在线a可以看的网站| 国产成人免费观看mmmm| 日韩高清综合在线| 久久精品国产鲁丝片午夜精品| 黄色日韩在线| 日本wwww免费看| 能在线免费看毛片的网站| 国产av一区在线观看免费| 熟女电影av网| 精品午夜福利在线看| 美女cb高潮喷水在线观看| 亚洲图色成人| 国产精品.久久久| 日日啪夜夜撸| 亚洲最大成人av| 99热这里只有是精品在线观看| 九九爱精品视频在线观看| 国产精品.久久久| 搡女人真爽免费视频火全软件| 亚洲欧洲日产国产| 久久久久九九精品影院| 国产亚洲一区二区精品| 国产成人a区在线观看| 亚洲国产高清在线一区二区三| 久久久久久久久久黄片| 国产精品久久久久久久久免| 久久欧美精品欧美久久欧美| 久久久久网色| 99视频精品全部免费 在线| 最近视频中文字幕2019在线8| 乱码一卡2卡4卡精品| 黄片无遮挡物在线观看| 亚洲欧美日韩高清专用| 熟女电影av网| 天天躁日日操中文字幕| 两性午夜刺激爽爽歪歪视频在线观看| 久久久久久大精品| 国产免费又黄又爽又色| 精品久久久久久电影网 | 全区人妻精品视频| 丝袜美腿在线中文| 精品少妇黑人巨大在线播放 | 特级一级黄色大片| 久久久久久大精品| 欧美潮喷喷水| 97超视频在线观看视频| 亚洲不卡免费看| 神马国产精品三级电影在线观看| 久久久久网色| 久久精品91蜜桃| 最近中文字幕高清免费大全6| 美女被艹到高潮喷水动态| 久久99热这里只有精品18| 建设人人有责人人尽责人人享有的 | 赤兔流量卡办理| 国产精品一区二区在线观看99 | 日韩欧美精品免费久久| 天堂影院成人在线观看| 国产精品.久久久| 亚洲欧美成人综合另类久久久 | 91狼人影院| 成人国产麻豆网| 欧美xxxx性猛交bbbb| 伊人久久精品亚洲午夜| av又黄又爽大尺度在线免费看 | 久久精品91蜜桃| 日韩三级伦理在线观看| 尤物成人国产欧美一区二区三区| 日韩欧美精品v在线| 成人性生交大片免费视频hd| 精品一区二区三区人妻视频| 性色avwww在线观看| 搞女人的毛片| 一级毛片久久久久久久久女| 91精品一卡2卡3卡4卡| 亚洲av免费在线观看| 欧美高清性xxxxhd video| 国产精品福利在线免费观看| 久久人人爽人人片av| 大话2 男鬼变身卡| 久久国内精品自在自线图片| 欧美日韩综合久久久久久| 日韩成人av中文字幕在线观看| 亚洲av中文字字幕乱码综合| 天堂√8在线中文| 国产av一区在线观看免费| av免费观看日本| 水蜜桃什么品种好| 成人毛片60女人毛片免费| 国模一区二区三区四区视频| av福利片在线观看| 免费黄色在线免费观看| 精品熟女少妇av免费看| 六月丁香七月| 少妇高潮的动态图| 精品免费久久久久久久清纯| 亚洲在久久综合| 狂野欧美激情性xxxx在线观看| 夜夜爽夜夜爽视频| 亚洲国产欧洲综合997久久,| av在线老鸭窝| 亚洲一级一片aⅴ在线观看| 亚洲人成网站在线播| 91aial.com中文字幕在线观看| 欧美xxxx性猛交bbbb| 身体一侧抽搐| 1024手机看黄色片| 亚洲中文字幕一区二区三区有码在线看| 精品久久久久久久末码| 国产精品国产高清国产av| 超碰av人人做人人爽久久| 人人妻人人看人人澡| 国产亚洲91精品色在线| 成人美女网站在线观看视频| 亚洲熟妇中文字幕五十中出| 亚洲三级黄色毛片| 在线免费观看的www视频| 日本三级黄在线观看| 97人妻精品一区二区三区麻豆| 免费黄色在线免费观看| 久久欧美精品欧美久久欧美| 麻豆乱淫一区二区| 只有这里有精品99| 成年免费大片在线观看| 国产真实伦视频高清在线观看| 在线免费观看不下载黄p国产| 国内精品美女久久久久久| 国模一区二区三区四区视频| 精品国产露脸久久av麻豆 | 欧美xxxx性猛交bbbb| 两个人的视频大全免费| 在线免费十八禁| 全区人妻精品视频| 亚洲四区av| 熟女电影av网| 99久国产av精品国产电影| 国产精品久久久久久久电影| 国产精品熟女久久久久浪| 黄色日韩在线| 一区二区三区乱码不卡18| 在线观看66精品国产| 一个人观看的视频www高清免费观看| 看免费成人av毛片| 免费搜索国产男女视频| 国产精品1区2区在线观看.| 亚洲aⅴ乱码一区二区在线播放| 天天一区二区日本电影三级| 亚洲欧美日韩卡通动漫| 欧美不卡视频在线免费观看| 国产精品久久视频播放| 夜夜看夜夜爽夜夜摸| 午夜免费激情av| 九九在线视频观看精品| 一本一本综合久久| 久久热精品热| 人妻系列 视频| 日本五十路高清| 青春草国产在线视频| 免费看a级黄色片| 日韩一区二区三区影片| 2021天堂中文幕一二区在线观| 日韩一区二区三区影片| 91av网一区二区| 成人二区视频| 欧美日韩精品成人综合77777| 亚洲欧美精品综合久久99| 亚洲精品成人久久久久久| 成人鲁丝片一二三区免费| 亚洲欧美精品专区久久| 久久草成人影院| 婷婷色综合大香蕉| 99久久人妻综合| 99热网站在线观看| 亚洲在线观看片| 欧美精品国产亚洲| 看黄色毛片网站| 国产亚洲最大av| 国产精品不卡视频一区二区| 日本爱情动作片www.在线观看| 日韩国内少妇激情av| 一区二区三区四区激情视频| 白带黄色成豆腐渣| 亚洲综合精品二区| 纵有疾风起免费观看全集完整版 | 亚洲国产成人一精品久久久| 九九久久精品国产亚洲av麻豆| 99久久人妻综合| 七月丁香在线播放| 青春草视频在线免费观看| 色哟哟·www| 赤兔流量卡办理| 中国国产av一级| 亚洲国产日韩欧美精品在线观看| 久久99热这里只频精品6学生 | 精品国产三级普通话版| 插阴视频在线观看视频| 亚洲国产最新在线播放| 中国美白少妇内射xxxbb| 床上黄色一级片| 高清在线视频一区二区三区 | 只有这里有精品99| 亚洲成人久久爱视频| 高清午夜精品一区二区三区| 美女内射精品一级片tv| av专区在线播放| 亚洲欧洲国产日韩| 蜜桃亚洲精品一区二区三区| 久久热精品热| 午夜免费激情av| 白带黄色成豆腐渣| 我要搜黄色片| 国产在线男女| 国产高清视频在线观看网站| av线在线观看网站| 亚洲成人中文字幕在线播放| 99热全是精品| 午夜福利网站1000一区二区三区| 丰满少妇做爰视频| 色综合色国产| 欧美性感艳星| 波多野结衣巨乳人妻| 五月玫瑰六月丁香| 蜜桃久久精品国产亚洲av| 久久99蜜桃精品久久| 国产片特级美女逼逼视频| 色网站视频免费| 亚洲aⅴ乱码一区二区在线播放| 久久亚洲国产成人精品v| 麻豆国产97在线/欧美| 久久人妻av系列| 亚洲欧美成人综合另类久久久 | eeuss影院久久| 99热这里只有是精品在线观看| 91久久精品电影网| 国产在视频线精品| 国产精品1区2区在线观看.| 91在线精品国自产拍蜜月| 国产精品99久久久久久久久| 免费观看人在逋| 亚洲国产日韩欧美精品在线观看| 国产亚洲最大av| av黄色大香蕉| 91av网一区二区| 成年免费大片在线观看| 日韩av不卡免费在线播放| 丰满少妇做爰视频| 久久久久久久久久久免费av| 搡老妇女老女人老熟妇| 国产午夜精品一二区理论片| 国产成人精品婷婷| 丝袜喷水一区| 久久99热这里只有精品18| 99热这里只有精品一区| 美女大奶头视频| 欧美3d第一页| 只有这里有精品99| 热99re8久久精品国产| 22中文网久久字幕| 中文乱码字字幕精品一区二区三区 | 99热这里只有是精品50| 亚洲av男天堂| 在线播放国产精品三级| 久久久久精品久久久久真实原创| 免费看av在线观看网站| 久久99精品国语久久久| 51国产日韩欧美| 中文字幕av成人在线电影| 亚洲国产色片| 美女脱内裤让男人舔精品视频| 欧美成人精品欧美一级黄| av在线观看视频网站免费| 成人av在线播放网站| 成年女人看的毛片在线观看| 精品久久久久久久末码| 黄色配什么色好看| 美女xxoo啪啪120秒动态图| 看片在线看免费视频| 国产亚洲91精品色在线| 国产大屁股一区二区在线视频| 精华霜和精华液先用哪个| 麻豆精品久久久久久蜜桃| 永久网站在线| 日韩欧美精品免费久久| 看十八女毛片水多多多| 亚洲av熟女| 免费看光身美女| 国产黄色小视频在线观看| 中文资源天堂在线| 久久久精品94久久精品| 精品酒店卫生间| 国产精品嫩草影院av在线观看| 日产精品乱码卡一卡2卡三| 99热全是精品| 日产精品乱码卡一卡2卡三| 免费黄色在线免费观看| 亚洲av日韩在线播放| 国产精品嫩草影院av在线观看| 欧美日韩一区二区视频在线观看视频在线 | 日韩欧美精品免费久久| 国产白丝娇喘喷水9色精品| 最近视频中文字幕2019在线8| 欧美变态另类bdsm刘玥| 有码 亚洲区| 亚洲丝袜综合中文字幕| 国产精品一区二区三区四区久久| 老师上课跳d突然被开到最大视频| 成人国产麻豆网| 久久精品久久久久久久性| 在线天堂最新版资源| 亚洲高清免费不卡视频| 一个人看的www免费观看视频| 亚洲aⅴ乱码一区二区在线播放| 亚洲成av人片在线播放无| 又粗又硬又长又爽又黄的视频| av黄色大香蕉| 精品久久久久久电影网 | 搡女人真爽免费视频火全软件| 老司机福利观看| 国产 一区精品| 久久精品久久久久久久性| 亚洲国产精品sss在线观看| 男人狂女人下面高潮的视频| 精品久久久久久久久亚洲| 久久综合国产亚洲精品| 欧美+日韩+精品| 最近中文字幕高清免费大全6| 亚洲成色77777| 一边摸一边抽搐一进一小说| 成年女人看的毛片在线观看| 男人的好看免费观看在线视频| 国产免费一级a男人的天堂| 国产真实乱freesex| 两性午夜刺激爽爽歪歪视频在线观看| 一个人观看的视频www高清免费观看| 你懂的网址亚洲精品在线观看 | 国语自产精品视频在线第100页| 免费观看的影片在线观看| 免费观看在线日韩| 99在线视频只有这里精品首页| 日韩精品青青久久久久久| 欧美成人免费av一区二区三区| 国产私拍福利视频在线观看| 亚洲在线观看片| 中国国产av一级| 国产精品.久久久| 日本一二三区视频观看| 国产精品久久久久久久电影| 最近的中文字幕免费完整| 黄片无遮挡物在线观看| 中文字幕免费在线视频6| 99热网站在线观看| 免费人成在线观看视频色| 久久久久久久午夜电影| 麻豆成人av视频| 亚洲精品影视一区二区三区av| 国产成人精品久久久久久| 成人性生交大片免费视频hd| 日产精品乱码卡一卡2卡三| 国产亚洲一区二区精品| 久久这里只有精品中国| 亚洲在线自拍视频| 噜噜噜噜噜久久久久久91| 伊人久久精品亚洲午夜| 亚洲高清免费不卡视频| 大话2 男鬼变身卡| 大香蕉97超碰在线| 久久久亚洲精品成人影院| 99热这里只有是精品在线观看| 神马国产精品三级电影在线观看| 韩国av在线不卡| 亚洲av.av天堂| 欧美人与善性xxx| 国产片特级美女逼逼视频| 久久亚洲精品不卡| 亚洲国产日韩欧美精品在线观看| 亚洲四区av| 最新中文字幕久久久久| 欧美高清成人免费视频www| 午夜老司机福利剧场| 日韩欧美精品v在线| 久久精品熟女亚洲av麻豆精品 | 亚洲最大成人手机在线| 欧美bdsm另类| 欧美高清成人免费视频www| 99久久精品国产国产毛片| 久久精品国产自在天天线| 人人妻人人看人人澡| 国产精华一区二区三区| 婷婷色综合大香蕉| 看黄色毛片网站| 国产亚洲精品久久久com| 在线观看一区二区三区| 人人妻人人看人人澡| 亚洲最大成人手机在线| 成人国产麻豆网| 尾随美女入室| 国产精品久久久久久精品电影小说 | 免费在线观看成人毛片| 亚洲自偷自拍三级| 网址你懂的国产日韩在线| 日韩一区二区三区影片| 欧美精品国产亚洲| 老司机影院毛片| 久久精品国产99精品国产亚洲性色| 高清av免费在线| 色网站视频免费| 女的被弄到高潮叫床怎么办| 狂野欧美激情性xxxx在线观看| 亚洲欧美精品自产自拍| 久久精品国产亚洲av天美| 成人漫画全彩无遮挡| 我的老师免费观看完整版|